Literature DB >> 3127415

Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.

M Kelijman1, L A Frohman.   

Abstract

Changes in plasma GH responses to GHRH (1 microgram/kg, iv) were assessed after dietary manipulations in obese and nonobese subjects to determine whether the impaired GH responsiveness to GHRH in obesity is the consequence of obesity per se or of altered food intake. The mean plasma GH response to GHRH in 10 obese subjects was significantly (P less than 0.05) higher after a 72-h fast than when they were eating their usual diet. Comparable increases were found when 6 of the subjects were studied after eating an 800 Cal/day diet for 6 weeks (P less than 0.05). Plasma glucose and insulin levels were lower and FFA levels higher after fasting, but not after the diet, compared to values on the usual diet. The mean plasma somatomedin-C (Sm-C) level was similar to that in nonobese subjects and was unaffected by dietary changes. The peak GH responses to GHRH before fasting were inversely correlated with plasma Sm-C levels (r = 0.64; P less than 0.05). Plasma GH responses to GHRH in normal weight subjects were also higher after fasting for 24 h (P less than 0.05) and 72 h (P less than 0.01) than after an overnight fast. Plasma glucose, insulin, and FFA changes were similar in the obese and normal weight subjects. Plasma Sm-C levels in the nonobese subjects were slightly lower after 72 h of fasting. We conclude that the increased plasma GH responsiveness to GHRH after fasting is not unique to obesity and is unlikely to reflect a reversal of the obesity-associated impairment of GH secretion. The increased plasma GH responsiveness to GHRH after as little as 24 h of fasting suggests that it is a consequence of acute nutrient deprivation rather than weight loss. The enhanced responses in obese subjects after 6 weeks of food restriction, in contrast, are probably a consequence of weight reduction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3127415     DOI: 10.1210/jcem-66-3-489

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Effect of an obesity prevention program focused on motivating environments in childhood: a school-based prospective study.

Authors:  Y Yang; B Kang; E Y Lee; H K Yang; H-S Kim; S-Y Lim; J-H Lee; S-S Lee; B-K Suh; K-H Yoon
Journal:  Int J Obes (Lond)       Date:  2017-02-20       Impact factor: 5.095

2.  The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.

Authors:  M L Drent; H J Adèr; E A van der Veen
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

3.  Assessment of GH/IGF-I axis in obesity by evaluation of IGF-I levels and the GH response to GHRH+arginine test.

Authors:  M Maccario; C Gauna; M Procopio; L Di Vito; R Rossetto; S E Oleandri; S Grottoli; C Ganzaroli; G Aimaretti; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

Review 4.  Effect of acute endurance and resistance exercise on endocrine hormones directly related to lipolysis and skeletal muscle protein synthesis in adult individuals with obesity.

Authors:  Dominique Hansen; Romain Meeusen; Annelies Mullens; Paul Dendale
Journal:  Sports Med       Date:  2012-05-01       Impact factor: 11.136

Review 5.  Growth hormone release during acute and chronic aerobic and resistance exercise: recent findings.

Authors:  Laurie Wideman; Judy Y Weltman; Mark L Hartman; Johannes D Veldhuis; Arthur Weltman
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

6.  The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors.

Authors:  Fernando Cordido; Jesús Garcia-Buela; Susana Sangiao-Alvarellos; Teresa Martinez; Ovidio Vidal
Journal:  Mediators Inflamm       Date:  2010-01-21       Impact factor: 4.711

7.  The growth hormone response to hexarelin in patients with Prader-Willi syndrome.

Authors:  M Cappa; G Raguso; T Palmiotto; A Faedda; F Gurreri; G Neri; R Deghenghi; S Loche
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

8.  The effect of caloric restriction interventions on growth hormone secretion in nonobese men and women.

Authors:  Leanne M Redman; Johannes D Veldhuis; Jennifer Rood; Steven R Smith; Donald Williamson; Eric Ravussin
Journal:  Aging Cell       Date:  2009-10-30       Impact factor: 9.304

Review 9.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

Review 10.  Mechanisms underlying the neuroendocrine response to physical exercise.

Authors:  A Leal-Cerro; A Gippini; M J Amaya; M Lage; J A Mato; C Dieguez; F F Casanueva
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.